Inhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 2,300 shares, an increase of 360.0% from the March 31st total of 500 shares. Based on an average trading volume of 4,600 shares, the days-to-cover ratio is currently 0.5 days.
Inhibitor Therapeutics Price Performance
OTCMKTS:INTI remained flat at $0.09 during trading hours on Friday. Inhibitor Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.30. The company has a 50 day moving average of $0.07 and a 200 day moving average of $0.08.
Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) last announced its earnings results on Friday, March 29th. The company reported ($0.01) earnings per share (EPS) for the quarter.
Inhibitor Therapeutics Company Profile
Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
Featured Articles
- Five stocks we like better than Inhibitor Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- MarketBeat Week in Review – 4/22 – 4/26
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks Leading the U.S. Agriculture Comeback
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
